Excision BioTherapeutics Stock
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Sign up today and learn more about Excision BioTherapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Excision BioTherapeutics Stock
Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
Funding History
September 2017 | $10.0M |
---|---|
December 2019 | $750K |
February 2021 | $60.0M |
Management
Board Member
Vasudev Bailey
Board Member
Ashok Krishnamurthi
CEO
Daniel Dombusch
CFO
Neal Kaplan
Interim Chief Business Officer
Michael Aberman
Principal Scientific Advisor
Khamel Khalili
Co-Founder
Rob Simmons
Press
patents - Apr, 14 2024
Computer-implemented systems and methods for targeting microhomology-mediated …patents - Apr, 14 2024
Compositions and methods for excision with single grnapatents - Apr, 14 2024
Compositions and methods of treatment for lytic and lysogenic virusespatents - Apr, 14 2024
Gene editing methods and compositions for eliminating risk of jc virus …finance - Jan, 19 2024
HIV Type-1 Market is Likely to Increase at a Steady Growth ...